Cannabinoids and Neuroprotection in Basal Ganglia Disorders
- 23 June 2007
- journal article
- review article
- Published by Springer Nature in Molecular Neurobiology
- Vol. 36 (1) , 82-91
Abstract
Cannabinoids have been proposed as clinically promising neuroprotective molecules, as they are capable to reduce excitotoxicity, calcium influx, and oxidative injury. They are also able to decrease inflammation by acting on glial processes that regulate neuronal survival and to restore blood supply to injured area by reducing the vasoconstriction produced by several endothelium-derived factors. Through one or more of these processes, cannabinoids may provide neuroprotection in different neurodegenerative disorders including Parkinson’s disease and Huntington’s chorea, two chronic diseases that are originated as a consequence of the degeneration of specific nuclei of basal ganglia, resulting in a deterioration of the control of movement. Both diseases have been still scarcely explored at the clinical level for a possible application of cannabinoids to delay the progressive degeneration of the basal ganglia. However, the preclinical evidence seems to be solid and promising. There are two key mechanisms involved in the neuroprotection by cannabinoids in experimental models of these two disorders: first, a cannabinoid receptor-independent mechanism aimed at producing a decrease in the oxidative injury and second, an induction/upregulation of cannabinoid CB2 receptors, mainly in reactive microglia, that is capable to regulate the influence of these glial cells on neuronal homeostasis. Considering the relevance of these preclinical data and the lack of efficient neuroprotective strategies in both disorders, we urge the development of further studies that allow that the promising expectatives generated for these molecules progress from the present preclinical evidence till a real clinical application.Keywords
This publication has 81 references indexed in Scilit:
- Cannabidiol reduced the striatal atrophy caused 3‐nitropropionic acidin vivoby mechanisms independent of the activation of cannabinoid, vanilloid TRPV1and adenosine A2AreceptorsEuropean Journal of Neuroscience, 2007
- Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: Importance of antioxidant and cannabinoid receptor-independent propertiesBrain Research, 2007
- Cannabinoid signallingLife Sciences, 2006
- Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonismNeurobiology of Disease, 2005
- In Vivo Calpain/Caspase Cross-talk during 3-Nitropropionic Acid-induced Striatal DegenerationJournal of Biological Chemistry, 2003
- Plant-derived, synthetic and endogenous cannabinoids as neuroprotective agentsBrain Research Reviews, 2003
- Release of Fatty Acid Amides in a Patient With Hemispheric StrokeStroke, 2002
- Treatment of Parkinson's with L-DOPA. The early discovery phase, and a comment on current problemsJournal of Neural Transmission, 2002
- Anandamide, but not 2‐arachidonoylglycerol, accumulates during in vivo neurodegenerationJournal of Neurochemistry, 2001
- CB1 cannabinoid receptor induction in experimental strokeAnnals of Neurology, 2000